WAVEMAN · COMPANY

KRRO · Korro Bio, Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

KRRO

Name: Korro Bio, Inc. (KRRO) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Korro Bio, Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001703647

CLUSTER · 11 INSIDERSFORM 144 · 17☆ WATCH

INSIDER NET · 180D

$15.9M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+181.5%

XBRL, annual

NET MARGIN

-1834.5%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$15.9M over 180 days

-$4.6M over 90 days · +$20.8M of it by a 10%+ holder

more than 96% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

68 funds added or opened last quarter

more than 53% of Pharma & Biotech

REVENUE

+181.5% year over year

more than 89% of Pharma & Biotech

MARGIN

-1834.5% net margin

below 93% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

9.8% of shares outstanding short · 9.2 days to cover · settled 2026-07-31

more than 75% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

11 insiders bought a net $15.9M, but 17 Form 144 notices ($5.2M) are queued to sell.

68 funds added or opened positions in the latest 13F quarter, of 108 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -47.7%

-47.7%12M

INSIDER BUYINSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

11 insiders reported buying shares.

The record shows a net $15.9M bought by insiders over 180 days, 68 funds added last quarter, $5.2M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Korro Bio, Inc. insiders bought a net $15.9M of stock across 71 Form 4 purchases and sales, with 11 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

FORMELA JEAN FRANCOIS

Director

SELL

2026-08-26

249.0

$3.5K

FORMELA JEAN FRANCOIS

Director

SELL

2026-08-26

51.0

$712

FORMELA JEAN FRANCOIS

Director

SELL

2026-08-19

23,584.0

$330.2K

FORMELA JEAN FRANCOIS

Director

SELL

2026-08-19

4,884.0

$68.4K

FORMELA JEAN FRANCOIS

Director

SELL

2026-08-11

1,775.0

$24.8K

71 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 66 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

Lynx1 Capital Management LP

3,076,592.0 sh

$40.5M

Nantahala Capital Management, LLC

1,320,072.0 sh

$17.4M

NEA Management Company, LLC

1,297,893.0 sh

$17.1M

Venrock Adviser, LLC

1,009,500.0 sh

$13.3M

Atlas Venture Life Science Advisors, LLC

962,884.0 sh

$12.7M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

Atlas Venture Fund XI, L.P.

FILED 2026-08-26

$3.4K

Atlas Venture Opportunity Fund II, L.P.

FILED 2026-08-26

$700

Atlas Venture Fund XI, L.P.

FILED 2026-08-19

$311.8K

Atlas Venture Opportunity Fund II, L.P.

FILED 2026-08-19

$64.6K

Atlas Venture Fund XI, L.P.

FILED 2026-08-11

$23.9K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

F/m Emerald Life Sciences Innovation ETF

$751.0K POSITION · AS OF 2026-02-28

0.8%

VANGUARD STRATEGIC SMALL-CAP EQUITY FUND

$1.0M POSITION · AS OF 2026-03-31

0.0%

iShares Micro-Cap ETF

$189.3K POSITION · AS OF 2026-03-31

0.0%

1290 VT Micro Cap Portfolio

$14.7K POSITION · AS OF 2026-03-31

0.0%

T. Rowe Price Extended Equity Market Index Fund

$73.6K POSITION · AS OF 2026-03-31

0.0%

Small Cap Core Fund

$24.8K POSITION · AS OF 2026-03-31

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 2 registered trials, 1 still enrolling or running — a status change here is dated weeks before the press release

Multi-phase

1 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2023-11
REVENUE	$6.4M	$2.3M	$0	—
OPERATING INCOME	$-121.9M	$-91.9M	$-84.5M	—
NET INCOME	$-117.3M	$-83.6M	$-81.2M	—
EPS (DILUTED)	-12.48	-9.37	-53.08	—
OPERATING CASH FLOW	$-78.6M	$-60.1M	$-67.3M	—
CASH	$21.8M	$55.6M	$166.2M	$36.6M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE